Spyre Therapeutics, Inc. · NASDAQ:SYRE
Albers Jeffrey W. sold 23,000 Spyre Therapeutics, Inc. shares (Form 4)
Traded Aug 7, 2026 · Filed Aug 10, 2026
On Aug 7, 2026, Albers Jeffrey W. (Director) sold 23,000 Spyre Therapeutics, Inc. shares at an average US$104.53 for US$2.4M under a trading plan, leaving 9,360 shares. Filed Aug 10, 2026 (Form 4).
- Sold
- 23,000 shares
- Price
- US$104.53 average (US$104.38 to US$104.68)
- Value
- US$2.4M
- Holding after
- 9,360 shares (held indirectly)
- Trading plan
- Yes (Made under a plan set in advance)
- Role
- Director
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 7, 2026 | Common Stock | Option exercise | 5,000 | US$10.39 | 5,000 | Direct |
| Aug 7, 2026 | Common Stock | Sale | 5,000 | US$104.47 | 0 | Direct |
| Aug 7, 2026 | Common Stock | Sale | 8,000 | US$104.38 | 19,360 | Indirect |
| Aug 7, 2026 | Common Stock | Sale | 10,000 | US$104.68 | 9,360 | Indirect |
Source
Related
- Spyre Therapeutics, Inc.
- Albers Jeffrey W.
- Spyre Therapeutics, Inc. shareholders
- Schedule 13D/A · Harwin Peter Evan · Oct 9, 2026
- Form 4 · Burrows Scott L · Oct 2, 2026
- Form 4 · King-Jones Heidy · Oct 2, 2026
- Form 4 · Turtle Cameron · Oct 2, 2026
- Schedule 13G · Paradigm Biocapital Advisors LP · Oct 1, 2026